Are children being vaccinated
against MMR within the
2017 US National Immunization Survey (NIS)2,a
Immunization rates indicate a need for earlier vaccination:
- 19 months: 87.7% (n=15,333)
- 24 months: 90.0% (n=15,333)
- 19-35 months: 91.5% (n=15,333)
- aData from a 2017 Centers for Disease Control (CDC) national survey (N=15,333) showed that an estimated 61% of children aged 13 months had received at least 1 dose of M-M-R®II vaccine. At 19 months, the percentage of children who received at least 1 dose of M-M-R®II vaccine was 87.7%, and 90% at 24 months. By months 19-35, the percentage of children who received at least 1 dose of M-M-R®II vaccine was 91.5%. The CDC analyzed data from the NIS. Immunization data were collected through telephone interviews via randomly selected numbers and confirmed through records supplied by the child’s health care providers. Vaccination coverage estimates include only children who had adequately completed provider-reported immunization records.
Indications and Usage for M-M-R®II
- M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age or older.
- The first dose of M-M-R®II is administered at 12 to 15 months of age and the second dose of M-M-R®II is administered at 4 to 6 years of age.
- M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) is contraindicated in certain individuals, including those with: a history of hypersensitivity to any component of the vaccine, including gelatin; a history of anaphylactic reaction to neomycin; individuals who are immunodeficient or immunosuppressed due to disease or medical therapy; an active febrile illness; active untreated tuberculosis; or those who are pregnant or are planning to become pregnant within the next month.
- Due caution should be employed in administration of M-M-R®II to persons with: a history of febrile seizure or family history of febrile seizures; immediate-type hypersensitivity reactions to eggs; thrombocytopenia.
- Vaccination should be deferred in individuals with a family history of congenital or hereditary immunodeficiency until the individual’s immune status has been evaluated and the individual has been found to be immunocompetent.
- Immune globulins (IG) and other blood products should not be given concurrently with M-M-R®II. The ACIP has specific recommendations for intervals between administration of antibody-containing products and live virus vaccines.
- The following adverse reactions have been identified during clinical trials or reported during post-approval use of M-M-R®II or its components: fever, headache, dizziness, rash, injection-site reactions, febrile convulsions, anaphylaxis and anaphylactoid reactions, arthritis, thrombocytopenia, encephalitis and encephalopathy.
DOSAGE AND ADMINISTRATION
- FOR SUBCUTANEOUS USE ONLY.
- M-M-R®II vaccine can be administered concurrently with other live viral vaccines. If not given concurrently, M-M-R®II vaccine should be given one month before or one month after administration of other live viral vaccines to avoid potential for immune interference.